中枢神经系统(CNS)疾病影响全球数百万人,相当比例的人经历耐药形式,而传统药物无法提供足够的癫痫发作控制。本摘要深入研究了最新进展和创新疗法,旨在解决中枢神经系统相关的耐药性癫痫(DRE)管理的复杂挑战。精准医学的理念开辟了癫痫医治的新门路。草药如姜黄素,银杏叶,人参,bacopamonnieri,ashwagandha,红景天通过多种机制影响BDNF途径。这些包括激活CREB,抑制NF-κB,调节神经递质,减少氧化应激,和抗炎作用。通过促进BDNF的表达和活性,这些草药支持神经可塑性,认知功能,和整体神经元健康。具有不同作用机制的新型抗癫痫药物(AED)在传统药物步履蹒跚的难治性病例中显示出疗效。此外,将现有药物重新用于抗癫痫药物是一种具有成本效益的策略,可以拓宽治疗选择范围.大麻二酚(CBD),源自大麻草药,它的抗惊厥特性引起了人们的关注,为难治性癫痫提供潜在的辅助治疗。总之,最新进展和创新疗法代表了管理耐药癫痫的多方面方法.利用精准医疗,神经刺激技术,新型药物,和补充疗法,临床医生可以优化治疗结果,提高难治性癫痫患者的预期寿命.基因测试和生物标志物识别现在允许针对个体患者概况定制的个性化治疗方法。利用下一代测序技术,研究人员已经阐明了基因突变。
Central Nervous System (CNS) disorders affect millions of people worldwide, with a significant proportion experiencing drug-resistant forms where conventional medications fail to provide adequate seizure control. This abstract delves into recent advancements and innovative therapies aimed at addressing the complex challenge of CNS-related drug-resistant epilepsy (DRE) management. The idea of precision medicine has opened up new avenues for epilepsy treatment. Herbs such as curcumin, ginkgo biloba, panax ginseng, bacopa monnieri, ashwagandha, and rhodiola rosea influence the BDNF pathway through various mechanisms. These include the activation of CREB, inhibition of NF-κB, modulation of neurotransmitters, reduction of oxidative stress, and anti- inflammatory effects. By promoting BDNF expression and activity, these herbs support neuroplasticity, cognitive function, and overall neuronal health. Novel antiepileptic drugs (AEDs) with distinct mechanisms of action demonstrate efficacy in refractory cases where traditional medications falter. Additionally, repurposing existing drugs for antiepileptic purposes presents a cost-effective strategy to broaden therapeutic choices. Cannabidiol (CBD), derived from cannabis herbs, has garnered attention for its anticonvulsant properties, offering a potential adjunctive therapy for refractory seizures. In conclusion, recent advances and innovative therapies represent a multifaceted approach to managing drug-resistant epilepsy. Leveraging precision medicine, neurostimulation technologies, novel pharmaceuticals, and complementary therapies, clinicians can optimize treatment outcomes and improve the life expectancy of patients living with refractory seizures. Genetic testing and biomarker identification now allow for personalized therapeutic approaches tailored to individual patient profiles. Utilizing next-generation sequencing techniques, researchers have elucidated genetic mutations.